Star Lake Technology: Net profit of 20.24 million yuan, to achieve a profit-making

March 25, 2014, Guangdong Zhaoqing Xinghu Biotech Co., Ltdreleased its 2013 annual report, with annual operating income of 903 million yuan, down 17.27% YoY, and a net profit attributable to shareholders of listed companies of 20.24 million yuanFuX
The main reason for the decline in operating income is the fierce competition in the leading product market, the decline in sales prices, the company adjusts the product structure, compressthes the production and sales of loss-making productsFuX
In terms of feed additive products, operating income was RMB49.78 million, down 72.64% YoY; operating costs were RMB54.02 million, down 71.86% YoY; and gross margin was 8.52%, down 3.02 percentage points YoYFuX
The company's sales revenue of biochemical drugs increased year-on-year, mainly due to the increase in sales revenue of adenosine and adenosine, the increase in sales revenue of food additives, mainly due to increased sales of IMP and I-G, the year-on-year decline in sales of feed additives, the sharp decrease in sales revenue of feed products during the current period, and the decrease in sales revenue of other new materials companies, which was caused by the decrease in sales of aluminum-pressing products and the export sales of subsidiariesFuXon March 25, 2014, Guangdong Zhaoqing Xinghu Biotech Co., Ltdreleased its 2013 annual report, which reduced its 2013 annual operating income by 903 million yuan, a decrease of 17.27 percent year-on-yearFuX
The main reason for the decline in operating income is the fierce competition in the leading product market, the decline in sales prices, the company adjusts the product structure, compressthes the production and sales of loss-making products FuX
　　In terms of feed additive products, operating income was RMB49.78 million, down 72.64% YoY; operating costs were RMB54.02 million, down 71.86% YoY; and gross margin was 8.52%, down 3.02 percentage points YoY FuX
　　The company's sales revenue of biochemical drugs increased year-on-year, mainly due to the increase in sales revenue of adenosine and adenosine, the increase in sales revenue of food additives, mainly due to increased sales of IMP and I-G, the year-on-year decline in sales of feed additives, the sharp decrease in sales revenue of feed products during the current period, and the decrease in sales revenue of other new materials companies, which was caused by the decrease in sales of aluminum-pressing products and the export sales of subsidiaries FuX
Share it on feed